ロード中...
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
The multikinase inhibitor sorafenib is under clinical investigation for the treatment of many solid tumors, but in most cases, the molecular target responsible for the clinical effect is unknown. Furthermore, enhancing the effectiveness of sorafenib using combination strategies is a major clinical c...
保存先:
| 出版年: | Int J Cancer |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Blackwell Publishing Ltd
2015
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4312923/ https://ncbi.nlm.nih.gov/pubmed/25080865 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.29113 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|